Global Alpha Capital Management’s Pacira BioSciences PCRX Stock Holding History

Global Alpha Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-68,360	Closed	-$1.77M	–	57
2025 Q4	$1.77M	Sell	68,360 -11,100	-14%	-$264K	0.11%	51
2025 Q3	$2.05M	Hold	79,460	–	–	0.12%	51
2025 Q2	$1.9M	Buy	79,460 +22,374	+39%	+$564K	0.12%	51
2025 Q1	$1.42M	Buy	57,086 +17,186	+43%	+$411K	0.1%	54
2024 Q4	$752K	Buy	39,900 +2,160	+6%	+$37.9K	0.05%	56
2024 Q3	$568K	Sell	37,740 -49,560	-57%	-$847K	0.04%	57
2024 Q2	$2.5M	Buy	87,300 +11,500	+15%	+$327K	0.18%	42
2024 Q1	$2.21M	Buy	75,800 +3,300	+5%	+$101K	0.16%	41
2023 Q4	$2.45M	Buy	+72,500	New	+$2.12M	0.2%	37

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Global Alpha Capital Management's PCRX Position: Q1 2026 in Review

Global Alpha Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 68,360 shares — an estimated $1.77M sold.

Global Alpha Capital Management first reported a position in PCRX in Q4 2023 and held it in 9 quarters. The position peaked at $2.5M in Q2 2024. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Global Alpha Capital Management reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Global Alpha Capital Management sold 68,360 Pacira BioSciences shares in Q1 2026, an estimated $1.77M.
Global Alpha Capital Management first reported a position in Pacira BioSciences in Q4 2023 and held it in 9 quarters.
Global Alpha Capital Management's Pacira BioSciences position peaked at $2.5M in Q2 2024.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Global Alpha Capital Management's 13F filing for Q1 2026, filed 11 May 2026.